OptiScan Biomedical to Present at 30th Annual J.P. Morgan Healthcare Conference

HAYWARD, Calif., Jan. 9, 2012 /PRNewswire/ -- OptiScan Biomedical Corporation, a developer of innovative continuous glucose monitoring systems for use in intensive care units (ICU), today announced that Peter Rule, chairman and chief executive officer, will present at the 30th Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2012 at 2:00 p.m. Pacific Time at the Westin St. Francis Hotel in San Francisco, CA.  

"Our selection as one of the few private companies that will present at this prestigious conference is just the latest in a string of key milestones for OptiScan which include receipt of CE Mark certification for use of our novel 'OptiScanner' system in the European Union and our first confirmed OptiScanner order in Italy," said Peter Rule, chairman and chief executive officer of OptiScan Biomedical.  "These exciting developments are the result of several years of dedicated effort and significant levels of invested capital and we look forward to sharing our latest data on the OptiScanner, as well as an update on commercialization efforts in Europe, at the J.P. Morgan conference." 

OptiScan is currently in the process of raising funding that will support the ongoing commercialization of the OptiScanner in Europe.  Inquiries regarding this financing should be directed to Patrick Nugent, OptiScan's chief financial officer, at 510-342-5803 or [email protected].

About OptiScan Biomedical
OptiScan Biomedical is the world leader in developing a glucose monitoring system for use in hospital intensive care units (ICU).  The company's lead product is the OptiScanner™, a first-of-its-kind automated, bedside glucose monitoring system that provides highly accurate, continuous monitoring of patients' glucose levels measured in plasma, as opposed to whole blood.  The system prominently displays glucose level trend data updated every 15 minutes to help manage patients' glucose levels within an optimum target range.  OptiScan has received CE Mark certification for the OptiScanner in the European Union and is in active discussions with the United States Food and Drug Administration regarding approval of the product in the U.S. 

The company is currently working to expand the capability of the OptiScanner platform technology by detecting additional analytes within the same blood sample, thereby providing additional information about the condition of a critically ill patient.

For more information visit: www.optiscancorp.com

SOURCE OptiScan Biomedical Corporation